- Home
- LNT vs ILMN Comparison
LNT vs ILMN Comparison
Compare LNT & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNT
- ILMN
- Stock Information
- Founded
- LNT 1917
- ILMN 1998
- Country
- LNT United States
- ILMN United States
- Employees
- LNT N/A
- ILMN N/A
- Industry
- LNT Power Generation
- ILMN Medical Specialities
- Sector
- LNT Utilities
- ILMN Health Care
- Exchange
- LNT Nasdaq
- ILMN Nasdaq
- Market Cap
- LNT 15.8B
- ILMN 15.9B
- IPO Year
- LNT N/A
- ILMN 2000
- Fundamental
- Price
- LNT $62.95
- ILMN $85.60
- Analyst Decision
- LNT Hold
- ILMN Buy
- Analyst Count
- LNT 8
- ILMN 18
- Target Price
- LNT $62.81
- ILMN $141.94
- AVG Volume (30 Days)
- LNT 2.4M
- ILMN 2.9M
- Earning Date
- LNT 05-01-2025
- ILMN 05-01-2025
- Dividend Yield
- LNT 3.23%
- ILMN N/A
- EPS Growth
- LNT N/A
- ILMN N/A
- EPS
- LNT 2.69
- ILMN N/A
- Revenue
- LNT $3,981,000,000.00
- ILMN $4,372,000,000.00
- Revenue This Year
- LNT $5.30
- ILMN $1.49
- Revenue Next Year
- LNT $3.29
- ILMN $5.03
- P/E Ratio
- LNT $23.40
- ILMN N/A
- Revenue Growth
- LNT N/A
- ILMN N/A
- 52 Week Low
- LNT $47.23
- ILMN $80.18
- 52 Week High
- LNT $66.54
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- LNT 54.37
- ILMN 28.17
- Support Level
- LNT $62.00
- ILMN $81.51
- Resistance Level
- LNT $64.28
- ILMN $92.90
- Average True Range (ATR)
- LNT 1.22
- ILMN 4.20
- MACD
- LNT -0.26
- ILMN 1.06
- Stochastic Oscillator
- LNT 22.96
- ILMN 32.46
About LNT Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electric customers and 425,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.